Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Eszopiclone (compound)

Name: eszopiclone
PubChem Compound ID: 969472
Molecular formula: C17H17ClN6O3
Molecular weight: 388.808 g/mol
138729-47-2; Eszopiclone; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; Eszopiclone [USAN:INN]; Estorra (TN); D02624; (plus)-Zopiclone; (S)-Zopiclone; Estorra.
show more »
Name: eszopiclone
Name (isomeric): DB00402
Drug Type: small molecule
Brand: Estorra, Lunesta
Category: Hypnotics and Sedatives
CAS number: 138729-47-2
Indication: For the treatment of insomnia
Eszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobut...
show more »
Mechanism of Action: The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes.
Absorption: Rapidly absorbed following oral administration
Protein binding: 52-59%
Biotransformation: Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation.
Route of elimination: Up to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites.
Half Life: 6 hours
Toxicity: Side effects include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste depending on doses.
Affected organisms: Humans and other mammals
Drug interaction:
TriprolidineThe CNS depressants, Triprolidine and Eszopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
VoriconazoleVoriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eszopiclone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of eszopiclone if voriconazole is initiated, discontinued or dose changed.
TelithromycinTelithromycin may reduce clearance of Eszopiclone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eszopiclone if Telithromycin is initiated, discontinued or dose changed.